cc-115 and Kidney-Neoplasms

cc-115 has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cc-115 and Kidney-Neoplasms

ArticleYear
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth.
    Aging, 2020, 10-27, Volume: 12, Issue:20

    CC-115 is a dual inhibitor of DNA-PKcs and mTOR, both are valuable therapeutic targets for renal cell carcinoma (RCC). Our results showed that CC-115 inhibited survival and proliferation of established RCC cell lines (786-O and A489) and primary human RCC cells. The dual inhibitor induced selective apoptosis activation in RCC cells, as compared to no cytotoxicity nor apoptotic effects toward normal renal epithelial cells. CC-115 inhibited DNA-PKcs and mTORC1/2 activation in RCC cells. It was however ineffective in DNA-PKcs-mTOR double knockout (DKO) 786-O cells. CC-115 induced feedback autophagy activation in RCC cells. Autophagy inhibitors or Beclin-1/Light chain 3 (LC3) silencing potentiated CC-115-induced anti-RCC cell activity. Conversely, ectopic overexpression of Beclin-1 inhibited CC-115-induced cytotoxicity. At last CC-115 oral administration inhibited 786-O subcutaneous xenograft growth in nude mice. Taken together, dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibited RCC cell growth.

    Topics: Animals; Carcinoma, Renal Cell; Cell Proliferation; DNA-Activated Protein Kinase; Female; Humans; Kidney Neoplasms; Mice; Pyrazines; TOR Serine-Threonine Kinases; Triazoles

2020